Date	Event	Description
9 October 2019	New citation required but conclusions have not changed	We included 15 studies in this review update: nine new studies and six studies from the original review (Shah 2016) that met the inclusion criteria. The findings in this update are consistent with those reported previously (Shah 2016).
9 October 2019	New search has been performed	A new search was performed. The review authors identified 15 unique studies, integrating nine new studies to six of those included in the previous Cochrane Review (Shah 2016). We used the terminology of lateral flow urine lipoarabinomannan assay (LF‐LAM). The Alere Determine™ TB LAM Ag assay was the only LF‐LAM test commercially available at the time of the review. New tests coming into the market, such as the FujiLAM, was not commercialized nor with any published data as of May 2018). We evaluated performance of LF‐LAM only at grade 1 on the update reference scale card (scale of 1 to 4) equivalent to grade 2 on the old reference scale card (scale 1 to 5). We evaluated LF‐LAM accuracy against a microbiological reference standard and did not include analysis against a composite reference standard. We grouped the analysis by studies among ‘Symptomatic' and ‘Unselected' participants instead of the previous terminology of ‘Diagnosis' and ‘Screening'. We changed the QUADAS judgements for some of the previously included studies.